ArticleFrontiers in pharmacology2026
Alternol inhibits GAPDH activity and disrupts glycolytic flux preferentially in cancer cells.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We and others demonstrated that the natural compound Alternol induces apoptosis preferentially in human cancer cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) participates in cellular glycolysis, important for energy homeostasis, especially in cancer cells. We recently discovered that Alternol interacts with GAPDH, along with 4 Krebs cycle enzymes. In this study, we characterized the mechanism for Alternol-GAPDH interaction and the functional significance. Methods: Multiple human prostate cancer cell lines and a benign prostate epithelial cell line were utilized in the experiments. Enzyme activity assay Results: Our data revealed that Alternol interacts with GAPDH protein on two sites, one of which is the NAD Conclusion: These results suggest that Alternol potently inhibits GAPDH activity and specifically disrupts glycolytic flux in cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.